Human Delta-like protein 4(DLL4) ELISA kit

Instructions
Code CSB-EL006949HU
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name delta-like 4 (Drosophila)
Alternative Names AOS6 ELISA Kit; Delta 4 ELISA Kit; delta 4 precursor ELISA Kit; Delta ligand 4 ELISA Kit; delta ligand 4 precursor ELISA Kit; Delta like 4 ELISA Kit; Delta like 4 homolog ELISA Kit; Delta like 4 protein ELISA Kit; Delta like canonical Notch ligand 4 ELISA Kit; Delta like protein 4 ELISA Kit; Delta-like 4 (Drosophila) ELISA Kit; Delta-like protein 4 ELISA Kit; Delta4 ELISA Kit; DLL 4 ELISA Kit; Dll4 ELISA Kit; DLL4_HUMAN ELISA Kit; Drosophila Delta homolog 4 ELISA Kit; hdelta2 ELISA Kit; Homeobox protein DLL-4 ELISA Kit; MGC126344 ELISA Kit; Notch ligand delta 2 ELISA Kit; Notch ligand DLL4 ELISA Kit; Notch ligand DLL4 precursor ELISA Kit; XDLL-4 ELISA Kit
Abbreviation DLL4
Uniprot No. Q9NR61
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 23.5 pg/mL-1500 pg/mL
Sensitivity 5.8 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Developmental Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human DLL4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %84
Range %81-89
1:2Average %94
Range %90-98
1:4Average %83
Range %80-86
1:8Average %87
Range %83-90
Recovery
The recovery of human DLL4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9591-99
EDTA plasma (n=4)10096-104
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
15002.261 2.298 2.280 2.098
7501.575 1.595 1.585 1.403
3750.989 0.975 0.982 0.800
187.50.643 0.606 0.625 0.443
940.434 0.429 0.432 0.250
470.317 0.338 0.328 0.146
23.50.267 0.278 0.273 0.091
00.181 0.183 0.182
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Involved in the Notch signaling pathway as Notch ligand
Gene References into Functions
  1. These data indicate that DLL4 represents a new prognostic biomarker for nonsmall cell lung cancer , and DLL4 overexpression inhibits cell proliferation and metastasis in vitro. PMID: 30226615
  2. Study demonstrates that DLL4 is important in regulating the tumour growth of hepatitis B virus (HBV)-associated hepatocellular carcinoma as well as the neovascularization and suppression of HBV replication. PMID: 30228780
  3. this study revealed that DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer. PMID: 29749499
  4. The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. PMID: 28946938
  5. Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
  6. epigenetic silencing and TP53 mutation have an effect on the expression of DLL4 in human cancer stem disorder PMID: 27542210
  7. the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
  8. Data suggest that Numb acts as a Notch antagonist by controlling intracellular destination and stability of the Notch ligand Delta-like 4 (DLL4) through a post-endocytic sorting process; Numb negatively controls DLL4 plasma membrane recycling through well-documented recycling regulator protein AP1. PMID: 29042443
  9. Results show that DLL4 is involved in SYNJ2BP-induced hepatocellular carcinoma (HCC) development though activating its pathway. PMID: 27440153
  10. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
  11. We show that GIT1, which also contains an ANK domain, inhibits the Notch1-Dll4 signaling pathway by competing with Notch1 ANK domain for binding to RBP-J in stalk cells PMID: 27926858
  12. Results provide evidence that DLL4 is associated with gastric cancer stem/progenitor cells (GCSPCs), and its expression impacts CSPC stemness characteristics associated with the Notch-1 pathway including self-renewal, differentiation, proliferation, and tumor formation. PMID: 27891816
  13. The authors present novel structures of human ligands Jagged2 and Delta-like4 and human Notch2, together with functional assays, which suggest that ligand-mediated coupling of membrane recognition and Notch binding is likely to be critical in establishing the optimal context for Notch signalling. PMID: 28572448
  14. Overexpression of DLL4 could significantly attenuate the cytotoxic effects of docetaxel in MCF-7 cells by increasing Bcl-2 expression, while decreasing Bax expression, apoptosis rate and DNA damage PMID: 27334972
  15. In gastric epithelial cells co-cultured with Helicobacter pylori, the expression level of the ligand DLL4 was found to be significantly increased. PMID: 27073072
  16. Low DLL4 abundance in tumour cells may predict the benefit from adjuvant gemcitabine therapy after PDAC resection. PMID: 27755532
  17. Angiogenesis in Infantile haemangioma (IH) appears to be controlled by DLL4 within the endothelium in a VEGF-A isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A isoforms to disease progression also indicates that IH may be associated with altered splicing. PMID: 26957058
  18. Dll4 modulates liver inflammatory response by down-regulating chemokine expression PMID: 27171900
  19. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
  20. Data show that the IgA/delta-like protein 4 (Delta-4)/Notch receptor (Notch) axis is not observed in IgG-dendritic cells (DCs). PMID: 27117596
  21. Data suggest that the vascular DLL4-Notch4 signaling and VEGF signaling complementing each other plays an important role in the progression of tumor angiogenesis in primary glioblastoma. PMID: 26472724
  22. our data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer. Therefore, DLL4 may be a potential clinical diagnostic marker for patients with early-stage cervical cancer. PMID: 26546434
  23. Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling PMID: 26870802
  24. DLL4 and JAG1 may have opposing effects on tumor angiogenesis in glioblastoma. PMID: 26546995
  25. Expression of D114 in the vessels of dermal microvasculature was shown to increase from 20 weeks of gestation to 20 years. PMID: 27487663
  26. Data indicate the role for altered forkhead box C2 (FoxC2)-Delta-like ligand 4 (Dll4)signaling in structural alterations of saphenous veins in patients with varicose veins. PMID: 26808710
  27. Antagonism of the DLL4-Notch signaling pathway might provide a potential therapeutic approach for breast cancer treatment by preventing angiogenesis. PMID: 26739060
  28. Activation of Dll4/Notch signaling led to increased expression of ephrin-B2 and subsequent inhibition of endothelial progenitor cells activity. PMID: 26212082
  29. DLL4 is a unique functional molecule of human circulating dendritic cells critical for directing Th1 and Th17 differentiation PMID: 26712946
  30. The expression of DLL4 was positively correlated with CD105-labeled MVD. PMID: 25986715
  31. The detection of Notch1 and Delta-like 4 expression in peripheral blood lymphocytes of renal transplant recipients can serve as a positive indicator for evaluating the diagnosis and treatment efficacy of the AR reaction. PMID: 26070613
  32. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. PMID: 25833803
  33. DLL4 and VEGFA expression was closely related to tumour diameter, clinical stage, histological grade and lymph node metastasis. PMID: 26111775
  34. DLL4/Notch1 and BMP9 interdependent signaling induces endothelial cell quiescence via P27KIP1/thrombospondin pathway. PMID: 26471266
  35. Overexpression of DLL4 is associated with thyroid tumor invasion and metastasis. PMID: 26241546
  36. Macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells. PMID: 26404485
  37. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. PMID: 26299364
  38. IL-23 could promote migration of human ESCC cells by activating DLL4/Notch1 signaling pathway PMID: 26062426
  39. expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer PMID: 24949865
  40. Dormant Dbf4 mRNA in immature GV oocytes is recruited by cytoplasmic polyadenylation during oocyte maturation and is dependent on MPF activity via its cytoplasmic polyadenylation element (CPE) PMID: 25348865
  41. High DLL4 expression is associated with T acute lymphoblastic leukemia. PMID: 25355291
  42. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture PMID: 25139440
  43. Dll4 expression is up-regulated in clear cell renal cell carcinoma patients, and predicts poor prognosis. PMID: 24966922
  44. Dengue virus up-regulates expression of notch ligands Dll1 and Dll4 through interferon-beta signalling pathway. PMID: 25041739
  45. Our data suggest that renal cell carcinoma progression is caused in part by activated DLL4/Notch signaling, interaction of endothelium and cells PMID: 24931473
  46. these results suggest that high expression of DLL4 is associated with axillary lymph node metastasis and a poor prognosis in breast cancer, suggesting its value as a diagnostic marker for breast cancer. PMID: 25260720
  47. These findings indicate a potential role for the Notch-1-Dll4 signaling pathway in foreign body-induced granulomatous reactions PMID: 24394305
  48. High expression of DLL4 is associated with metastasis in breast cancer. PMID: 24696220
  49. findings suggest that ADAM10/Dll4 signaling is a major signaling pathway in ECs driving inflammatory events involved in inflammation and immune cell recruitment PMID: 25130545
  50. Dll4-containing exosomes increase endothelial cell motility while suppressing their proliferation. PMID: 24504253

Show More

Hide All

Involvement in disease Adams-Oliver syndrome 6 (AOS6)
Subcellular Location Cell membrane, Single-pass type I membrane protein
Tissue Specificity Expressed in vascular endothelium.
Database Links

HGNC: 2910

OMIM: 605185

KEGG: hsa:54567

STRING: 9606.ENSP00000249749

UniGene: Hs.511076

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1